Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now later-stage tilt small index

Non-Melanoma Skin Cancer: later-stage trial registry

3 of 8 indexed Non-Melanoma Skin Cancer trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 3 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Non-Melanoma Skin Cancer: 8 US clinical trials tracked, 3 recruiting.

Non-Melanoma Skin Cancer is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Wright State University, running 2 of these trials.

Enrollment posture brief

Registry condition non-melanoma-skin-cancer

OPEN 3 | RECR 38% | LATE 2 | EARLY 0 | RANK #2176 | SPON 2

Nearest open-share peer: Acute-graft-versus-host Disease (38% recruiting · 8 trials)

Activity, Motor75%Achalasia50%Non-Melanoma Skin Cancer (th…38%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near Non-Melanoma Skin Cancer

Non-Melanoma Skin Cancer lists 3 open slots (38% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Non-Melanoma Skin Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Non-Melanoma Skin Cancer is recruiting below its size-band peers.

    3 of 8 indexed trials (37.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Non-Melanoma Skin Cancer research.

    Wright State University accounts for 2 of 8 trials (25%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Non-Melanoma Skin Cancer trials plan to enrol fewer than 100 people.

    Median target enrolment is 80 among the 8 trials that report a genuine target (sentinel values excluded). 6 of those (75%) plan for fewer than 100 participants.

  4. Non-Melanoma Skin Cancer research is mostly interventional.

    6 interventional and 2 observational studies make up this index (75% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 31Phase 41

Phase Distribution

PhaseTrial count
Phase 3 1
Phase 4 1

Named interventions

Most-linked intervention names on Non-Melanoma Skin Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Fractionated Laser Resurfacing Device
2 trials
Electronic Brachytherapy Procedure
1 trials
etanercept Drug
1 trials
Reconstituted grape powder Other
1 trials
sentinel lymph node biopsy (SLNB) Procedure
1 trials
Acetaminophen Drug
1 trials

US sites by state

Facility locations filed on Non-Melanoma Skin Cancer trials. A trial with sites in several states counts in each.

Ohio 2 trials
Alabama 2 trials
Pennsylvania 1 trials
Nevada 1 trials
Massachusetts 1 trials
Indiana 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Non-Melanoma Skin Cancer page

8 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-Melanoma Skin Cancer condition card totals 8 registered trials; most-linked intervention Fractionated Laser Resurfacing; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.